fluorouracil has been researched along with Dihydropyrimidine Dehydrogenase Deficiency in 132 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Dihydropyrimidine Dehydrogenase Deficiency: An autosomal recessive disorder affecting DIHYDROPYRIMIDINE DEHYDROGENASE and causing familial pyrimidinemia. It is characterized by thymine-uraciluria in homozygous deficient patients. Even a partial deficiency in the enzyme leaves individuals at risk for developing severe 5-FLUOROURACIL-associated toxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dihydropyrimidine dehydrogenase (DPD) deficiency is a pharmacogenetic syndrome associated with potentially life-threatening toxicity following the administration of standard doses of 5-fluorouracil." | 8.82 | Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. ( Diasio, R; Ezzeldin, H, 2004) |
| " These individuals are typically asymptomatic until exposed to 5-fluorouracil (5-FU) or capecitabine (which forms 5-FU) for treatment of gastrointestinal or breast cancer." | 8.02 | Testing for dihydropyrimidine dehydrogenase deficiency in New Zealand to improve the safe use of 5-fluorouracil and capecitabine in cancer patients. ( Burns, K; Findlay, M; Helsby, N; Porter, D; Strother, M, 2021) |
| "500 mg/m(2) uracil was administered orally to 12 subjects with stages II-III colorectal cancer (CRC) who were treated in the adjuvant setting and to 12 subjects with stage IV metastasized CRC, all treated with CAP containing therapy." | 7.81 | Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ( Gelderblom, H; Guchelaar, HJ; Maring, JG; Opdam, F; van Kuilenburg, AB; van Staveren, MC, 2015) |
| "In Nordic countries, the standard treatment of colorectal cancer (CRC) in the adjuvant setting is bolus 5-fluorouracil (5-FU) plus leucovorin alone or in combination with oxaliplatin." | 7.78 | Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2012) |
| "5-fluorouracil chemotherapy in patients with dihydropyrimidine dehydrogenase deficiency, can give rise to ocular and cutaneous toxicity." | 7.77 | A bilateral cicatricial ectropion and bilateral upper lid shortening caused by 5-fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. ( Kemp, E; McDonald, A; Obi, EE, 2011) |
| "5-fluorouracil (5-FU) is a chemotherapeutic agent widely used in the treatment of solid malignancies, especially in colorectal cancer." | 7.72 | Lethal toxicity after 5-fluorouracil chemotherapy and its possible relationship to dihydropyrimidine dehydrogenase deficiency: a case report and review of the literature. ( Aparicio, J; Calderero, V; Díaz, R; Guerrero, A; Pellín, L; Segura, A, 2004) |
| "DPD deficiency was suspected because he developed many severe adverse events of capecitabine early and was finally confirmed based on the finding of a low DPD activity level in peripheral blood mononuclear cells." | 6.82 | Severe Gastrointestinal Disorder Due to Capecitabine Associated with Dihydropyrimidine Dehydrogenase Deficiency: A Case Report and Literature Review. ( Akutsu, D; Fukuda, S; Hagiwara, Y; Ikeda, N; Inagaki, Y; Kobayashi, M; Moriwaki, T; Narasaka, T; Niisato, Y; Onoda, T; Suzuki, H; Tange, Y; Tomisaki, R; Tsuchiya, K; Tsuji, M; Yamada, K; Yamada, T; Yamamoto, Y, 2022) |
| "Capecitabine has become a standard treatment option for metastatic breast cancer, as a single agent or in combination." | 6.50 | Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature. ( Aftimos, PG; Errihani, H; Mokrim, M; Piccart-Gebhart, M, 2014) |
| "Uridine triacetate has been shown to be an effective antidote against mortality and toxicity caused by either overdoses or exaggerated susceptibility to the widely used anticancer agents 5-fluorouracil (5-FU) and capecitabine." | 5.48 | Prompt treatment with uridine triacetate improves survival and reduces toxicity due to fluorouracil and capecitabine overdose or dihydropyrimidine dehydrogenase deficiency. ( Bamat, MK; Garcia, RAG; Saydoff, JA; von Borstel, RW, 2018) |
| "The patient underwent sigmoidectomy for sigmoid cancer and was treated with capecitabine as adjuvant chemotherapy." | 5.42 | [Suspected dihydropyrimidine dehydrogenase deficiency in a patient receiving capecitabine as adjuvant chemotherapy after colon resection]. ( Nagai, K; Ohara, Y; Okuda, Y; Yamamoto, M, 2015) |
| "This patient with DPD deficiency manifested a variant of HFS." | 5.33 | Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. ( Diasio, R; Elfiky, A; Saif, MW, 2006) |
| "A 37-year-old female with gastric cancer underwent a curative operation, followed by adjuvant chemotherapy consisting of 5-FU and epirubicin." | 5.33 | Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency. ( Baek, JH; Hong, YJ; Kim, DH; Kim, JG; Kim, SN; Lee, KB; Sohn, SK, 2006) |
| "5-Fluorouracil (5-FU) is a mainstay for treating colorectal cancer, alone or more frequently as part of combination therapies." | 4.86 | Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? ( Ciccolini, J; Dahan, L; Gross, E; Lacarelle, B; Mercier, C, 2010) |
| "Dihydropyrimidine dehydrogenase (DPD) deficiency is a pharmacogenetic syndrome associated with potentially life-threatening toxicity following the administration of standard doses of 5-fluorouracil." | 4.82 | Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. ( Diasio, R; Ezzeldin, H, 2004) |
| " Patients with a (partial) dihydropyrimidine dehydrogenase deficiency proved to be at risk of developing severe toxicity after the administration of 5FU." | 4.82 | Pyrimidine degradation defects and severe 5-fluorouracil toxicity. ( Meinsma, R; van Gennip, AH; van Kuilenburg, AB, 2004) |
| " These individuals are typically asymptomatic until exposed to 5-fluorouracil (5-FU) or capecitabine (which forms 5-FU) for treatment of gastrointestinal or breast cancer." | 4.02 | Testing for dihydropyrimidine dehydrogenase deficiency in New Zealand to improve the safe use of 5-fluorouracil and capecitabine in cancer patients. ( Burns, K; Findlay, M; Helsby, N; Porter, D; Strother, M, 2021) |
| "A 63-year-old Japanese male with stomach adenocarcinoma received oral 5-fluorouracil derivative, cisplatin and trastuzumab chemotherapy." | 3.96 | A Japanese Patient with Gastric Cancer and Dihydropyrimidine Dehydrogenase Deficiency Presenting with DPYD Variants. ( Fujiki, S; Hiratsuka, A; Ishiguro, M; Kawai, D; Ogura, K; Okada, H; Takeda, H; Takenaka, R; Tsugeno, H, 2020) |
| "500 mg/m(2) uracil was administered orally to 12 subjects with stages II-III colorectal cancer (CRC) who were treated in the adjuvant setting and to 12 subjects with stage IV metastasized CRC, all treated with CAP containing therapy." | 3.81 | Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ( Gelderblom, H; Guchelaar, HJ; Maring, JG; Opdam, F; van Kuilenburg, AB; van Staveren, MC, 2015) |
| "In Nordic countries, the standard treatment of colorectal cancer (CRC) in the adjuvant setting is bolus 5-fluorouracil (5-FU) plus leucovorin alone or in combination with oxaliplatin." | 3.78 | Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2012) |
| "5-fluorouracil chemotherapy in patients with dihydropyrimidine dehydrogenase deficiency, can give rise to ocular and cutaneous toxicity." | 3.77 | A bilateral cicatricial ectropion and bilateral upper lid shortening caused by 5-fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. ( Kemp, E; McDonald, A; Obi, EE, 2011) |
| "Hand-foot syndrome (HFS), the most common toxicity of capecitabine, is characterized by tingling, numbness, pain, erythema, dryness, rash, swelling, increased pigmentation, and/or pruritus of the palmar and/or plantar surfaces of the hands and/or feet." | 3.76 | Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine. ( Abali, H; Disel, U; Gürkut, O; Kaleağasi, H; Mertsoylu, H; Ozyilkan, O; Saif, MW, 2010) |
| "African-American patients with colorectal cancer were observed to have increased 5-fluorouracil (5-FU)-associated toxicity (leukopenia and anemia) and decreased overall survival compared with Caucasian patients." | 3.73 | Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. ( Desmond, RA; Diasio, RB; Fourie, J; Mattison, LK; Modak, A; Saif, MW, 2006) |
| "5-fluorouracil (5-FU) is a chemotherapeutic agent widely used in the treatment of solid malignancies, especially in colorectal cancer." | 3.72 | Lethal toxicity after 5-fluorouracil chemotherapy and its possible relationship to dihydropyrimidine dehydrogenase deficiency: a case report and review of the literature. ( Aparicio, J; Calderero, V; Díaz, R; Guerrero, A; Pellín, L; Segura, A, 2004) |
| " In this review, we survey the evidence-based pharmacogenetics and therapeutic recommendations regarding DPYD (the gene encoding DPD) genotyping and DPD phenotyping to prevent toxicity and optimize dosing adaptation before FP administration." | 3.01 | Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency. ( Barin-Le Guellec, C; Boige, V; Chouchana, L; Ciccolini, J; Etienne-Grimaldi, MC; Loriot, MA; Narjoz, C; Pallet, N; Taieb, J; Thomas, F; Zaanan, A, 2023) |
| "DPD deficiency was suspected because he developed many severe adverse events of capecitabine early and was finally confirmed based on the finding of a low DPD activity level in peripheral blood mononuclear cells." | 2.82 | Severe Gastrointestinal Disorder Due to Capecitabine Associated with Dihydropyrimidine Dehydrogenase Deficiency: A Case Report and Literature Review. ( Akutsu, D; Fukuda, S; Hagiwara, Y; Ikeda, N; Inagaki, Y; Kobayashi, M; Moriwaki, T; Narasaka, T; Niisato, Y; Onoda, T; Suzuki, H; Tange, Y; Tomisaki, R; Tsuchiya, K; Tsuji, M; Yamada, K; Yamada, T; Yamamoto, Y, 2022) |
| "DPD deficiency is a pharmacogenetics syndrome associated with severe/lethal toxicities upon 5-FU or capecitabine intake." | 2.76 | DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity. ( Bagarry-Liegey, D; Blesius, A; Brunet, C; Chefrour, M; Ciccolini, J; Dahan, L; Duffaud, F; Favre, R; Ferri-Dessens, RM; Frances, N; Giovanni, A; Lacarelle, B; Marouani, H; Mercier, C; Seitz, JF; Varoquaux, A; Yang, CG; Zanaret, M, 2011) |
| "It is now well established that DPD deficiency could lead to severe toxicities and, thus, require dose reduction in deficient patients." | 2.58 | [5-fluorouracil therapeutic drug monitoring: Update and recommendations of the STP-PT group of the SFPT and the GPCO-Unicancer]. ( Boyer, JC; Chatelut, E; Ciccolini, J; Evrard, A; Goirand, F; Guilhaumou, R; Launay, M; Lemaitre, F; Paludetto, MN; Schmitt, A, 2018) |
| "Capecitabine has become a standard treatment option for metastatic breast cancer, as a single agent or in combination." | 2.50 | Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature. ( Aftimos, PG; Errihani, H; Mokrim, M; Piccart-Gebhart, M, 2014) |
| "DPD-deficient cancer patients may be at risk of severe and sometimes lethal toxicity after the administration of 5-FU." | 2.48 | [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil]. ( Dołegowska, B; Ostapowicz, A, 2012) |
| " Because of this, long term administration of such antibiotics could induce depletion of carnitine from the body and lead to low ketotic hypoglycemia, convulsion and consciousness disturbance." | 2.45 | Children's toxicology from bench to bed--Liver injury (1): Drug-induced metabolic disturbance--toxicity of 5-FU for pyrimidine metabolic disorders and pivalic acid for carnitine metabolism. ( Ito, T, 2009) |
| "The treatment of cancer patients with 5-fluorouracil (5FU)-based chemotherapy can be accompanied by severe and sometimes lethal toxicity." | 2.43 | Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question. ( van Kuilenburg, AB, 2006) |
| "Patients with a partial DPD deficiency have an increased risk of developing grade IV neutropenia." | 2.42 | Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. ( van Kuilenburg, AB, 2004) |
| "Indeed, the rate of DPD deficiency decreased from 86." | 1.91 | Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping. ( Ciccolini, J; Derain, L; Guitton, J; Launay, M; Parant, F; Royer, B; Thomas, F, 2023) |
| "Compared with no screening for DPD deficiency, DPYD genotyping increased per-patient costs by $78 and improved survival by 0." | 1.72 | Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer. ( Brooks, GA; Busam, JA; Daly, AT; Tapp, S; Tosteson, ANA, 2022) |
| "Uridine was significantly higher in the low DPD activity group and is a precursor of U involved in pyrimidine metabolism; therefore, we speculated that DPD deficiency can influence uridine levels in plasma." | 1.72 | Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase. ( Cho, JY; Jang, IJ; Jeon, I; Kang, J; Kim, AH; Lee, S; Oh, J, 2022) |
| " Uncertainty remains regarding optimal dosing practice." | 1.72 | Treating patients with dihydropyrimidine dehydrogenase (DPD) deficiency with fluoropyrimidine chemotherapy since the onset of routine prospective testing-The experience of a large oncology center in the United Kingdom. ( Essapen, S; Howlett, S; Wang, L, 2022) |
| "2%) US medical oncologists, of whom 98% strongly or somewhat agree that patients with dihydropyrimidine dehydrogenase (DPD) deficiency have increased toxicity risk and 96% would modify FP dosing for a patient with known DPD deficiency." | 1.72 | Survey of US Medical Oncologists' Practices and Beliefs Regarding ( Henry, NL; Hertz, DL; Koo, K; Pasternak, AL; Sahai, V, 2022) |
| " Tolerance was good and 5-FU dosing was next shifted to 25% reduction, then further shifted to normal dosing at the 5th course, with still no sign for drug-related toxicities." | 1.72 | Renal impairment and DPD testing: Watch out for false-positive results! ( Carriat, L; Ciccolini, J; Quaranta, S; Rony, M; Solas, C, 2022) |
| " 121 Kurdish patients receiving fluoropyrimidine derivatives were enrolled, and clinical information regarding the dosage and toxicity was analyzed." | 1.72 | Introducing a simple and cost-effective RT-PCR protocol for detection of DPYD*2A polymorphism: the first study in Kurdish population. ( Abdi, M; Fotoohi, A; Fotouhi, O; Ghaderi, B; Omid-Shafa'at, R; Salmani, M; Vahabzadeh, Z, 2022) |
| "Screening for DPD deficiency should be implemented in practice." | 1.72 | Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur). ( Bm Claes, K; Borbath, I; Casneuf, V; Demey, W; Geboes, KP; Haufroid, V; Van den Eynde, M; Verheezen, Y; Verstraete, AG, 2022) |
| "Consensus guidelines exist for genotype-guided fluoropyrimidine dosing based on variation in the gene dihydropyrimidine dehydrogenase (DPYD)." | 1.62 | Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events. ( Choi, YH; Keller, D; Kim, RB; Legan, RM; Lenehan, J; Mailloux, J; Medwid, S; Nevison, S; Panuganty, V; Povitz, BL; Sarma, S; Schwarz, UI; Siebring, V; Teft, WA; Welch, S; Wigle, TJ; Winquist, E, 2021) |
| " From the clinical course, we suspected that the severe adverse effects were caused due to a deficiency of DPD." | 1.62 | [A Case of Colon Cancer with Suspected DPD Deficiency Causing Severe Adverse Effects following Adjuvant Chemotherapy with Capecitabine]. ( Aoki, H; Araki, H; Arata, T; Katsuda, K; Kimura, Y; Minagi, H; Nagahisa, S; Ogawa, T; Tanakaya, K; Taniguchi, F; Watanabe, M, 2021) |
| " Our study is the first to show that DPYD*2A genotype-guided dosing appears to have no negative effect on effectiveness of fluoropyrimidine-based chemotherapy, while resulting in significantly improved patient safety." | 1.51 | Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis. ( Beijnen, JH; Cats, A; de Boer, A; Deenen, MJ; Henricks, LM; Meulendijks, D; Schellens, JHM; van Merendonk, LN, 2019) |
| " Severe (grade ≥III) toxicity in DPYD variant allele carriers receiving upfront FP dose reductions according to pharmacogenetic dosing guidelines and DPYD variant allele carriers not receiving FP dose reductions was compared with DPYD wild-type patients receiving standard dose of FPs in CRT." | 1.48 | Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers. ( Cecchin, E; Dreussi, E; Fiocco, M; Gelderblom, H; Guchelaar, HJ; Henricks, LM; Lunenburg, CATC; Meulendijks, D; Peters, FP; Schellens, JHM; Swen, JJ; Toffoli, G, 2018) |
| "Uridine triacetate has been shown to be an effective antidote against mortality and toxicity caused by either overdoses or exaggerated susceptibility to the widely used anticancer agents 5-fluorouracil (5-FU) and capecitabine." | 1.48 | Prompt treatment with uridine triacetate improves survival and reduces toxicity due to fluorouracil and capecitabine overdose or dihydropyrimidine dehydrogenase deficiency. ( Bamat, MK; Garcia, RAG; Saydoff, JA; von Borstel, RW, 2018) |
| "Uracil was superior to the dihydrouracil/uracil ratio as a predictor of severe toxicity." | 1.46 | Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. ( Aliev, A; Beijnen, JH; Cats, A; de Boer, A; de Vries, N; Deenen, MJ; Henricks, LM; Jacobs, BAW; Mandigers, CMPW; Meulendijks, D; Rosing, H; Schellens, JHM; Soesan, M; van Werkhoven, E, 2017) |
| " A lethal toxicity in two DPD patients suggests that fluoropyrimidines combined with other therapies such as radiotherapy might be particularly toxic for DPD deficient patients." | 1.46 | Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing. ( Dezentjé, V; Dobritzsch, D; Hennekam, RC; Hertz, JM; Jansen, RL; Knegt, LC; Los, M; Maurer, D; Meijer, J; Meinsma, R; van Huis-Tanja, LH; van Kampen, RJ; van Kuilenburg, AB; Zoetekouw, L, 2017) |
| "In line with partial DPD deficiency in both patients, sequence analysis of DPD cDNA demonstrated a normal-sized (wild type) cDNA fragment of 486 bp, as well as a larger-sized (mutant) 530-bp fragment containing an aberrant 44-bp insertion in intron 10." | 1.43 | Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines. ( Aliev, A; Beijnen, JH; Cats, A; de Graaf, H; Henricks, LM; Jacobs, BA; Meijer, J; Meulendijks, D; Rozeman, L; Schellens, JH; van Kuilenburg, AB, 2016) |
| "5 weeks (range 3-4 weeks), indicating that Vistogard might be able to delay 5-FU toxicity despite higher doses than standard bolus dose of 5-FU used in gastrointestinal malignancies and the appearance of a potentially less toxic adverse effect of 5-FU at an unusual site (cutaneous) in one patient." | 1.43 | Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency. ( Diasio, RB; Saif, MW, 2016) |
| "This feasibility study shows how simplified DPD-based adaptive dosing of 5-FU can reduce sharply the incidence of treatment-related severe toxicities while maintaining efficacy as part of routine clinical practice in digestive oncology." | 1.43 | Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer. ( Ciccolini, J; Dahan, L; Duluc, M; Duval, M; Lacarelle, B; Launay, M; Milano, G; Rodallec, A; Seitz, JF, 2016) |
| "The patient underwent sigmoidectomy for sigmoid cancer and was treated with capecitabine as adjuvant chemotherapy." | 1.42 | [Suspected dihydropyrimidine dehydrogenase deficiency in a patient receiving capecitabine as adjuvant chemotherapy after colon resection]. ( Nagai, K; Ohara, Y; Okuda, Y; Yamamoto, M, 2015) |
| "Depending on the type of cancer, physicians use the generally accepted schema of treatment, for example pharmacotherapy." | 1.39 | [Dihydropirymidine dehydrogenase (DPD)--a toxicity marker for 5-fluorouracil?]. ( Dołegowska, B; Jedrzychowska, A, 2013) |
| " We summarize evidence from the published literature supporting this association and provide dosing recommendations for fluoropyrimidines based on DPYD genotype (updates at http://www." | 1.39 | Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. ( Caudle, KE; Diasio, RB; Klein, TE; McLeod, HL; Schwab, M; Swen, JJ; Thorn, CF, 2013) |
| " So far, only very limited information is available regarding the pharmacokinetics of 5FU in patients with a (partial) DPD deficiency and no limited sampling models have been developed taking into account the non-linear pharmacokinetic behaviour of 5FU." | 1.38 | Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy. ( Behnke, D; Häusler, P; Jabschinsky, K; Maring, JG; Proost, JH; Schalhorn, A; Schwabe, W; Tanck, MW; Terborg, C; van Kuilenburg, AB, 2012) |
| "5-Fluorouracil (5-FU) is a mainstay for treating various solid tumours in adults, including digestive and head and neck cancers." | 1.37 | 5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases. ( Ciccolini, J; Cordier, PY; Lacarelle, B; Mercier, C; Nau, A; Oliver, M; Peytel, E, 2011) |
| "Patients with a DPD deficiency can experience severe toxicity of 5-FU." | 1.36 | [Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency]. ( Bontemps, H; Coursier, S; Emptoz, J; Guillermet, A; Martelet, S; Villier, C, 2010) |
| "Thus, a DPD deficiency could be predicted from 5FU blood concentrations measured after the administration of a test dose of 5FU." | 1.35 | Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14+1G > A mutation in the dihydropyrimidine dehydrogenase gene. ( Behnke, D; Hausler, P; Jabschinsky, K; Maring, JG; Schalhorn, A; Schmalenberg, H; Schwabe, W; Terborg, C; van Kuilenburg, AB, 2008) |
| " In this work, an artificial receptor in the format of molecularly imprinted polymer (MIP) brush 'grafted to' the surface of sol-gel immobilized on cost-effective homemade solid-phase microextraction (SPME) fibers, individually imprinted with either of Ura and 5FU, was used in combination with a voltammetric sensor duly modified with the same MIP." | 1.35 | Ultratrace analysis of uracil and 5-fluorouracil by molecularly imprinted polymer brushes grafted to silylated solid-phase microextraction fiber in combination with complementary molecularly imprinted polymer-based sensor. ( Patel, AK; Prasad, BB; Sharma, PS; Singh, M; Srivastava, S; Tiwari, K, 2009) |
| "Syndrome of DPD deficiency manifests as diarrhea, stomatitis, mucositis, and neurotoxicity and in some cases death." | 1.34 | DPYD*2A mutation: the most common mutation associated with DPD deficiency. ( Diasio, RB; Ezzeldin, H; Saif, MW; Sellers, S; Vance, K, 2007) |
| "8% (3/38) and was accompanied by severe Gr 4 toxic symptoms (neutropenia, mucositis, diarrhea)." | 1.34 | [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer]. ( Adleff, V; Budai, B; Hitre, E; Komlósi, V; Kralovánszky, J; Pap, E; Réti, A, 2007) |
| "Pseudomembranous colitis is frequently associated with antibiotics and more rarely with chemotherapeutic agents such as 5-fluorouracil." | 1.33 | Pseudomembranous colitis associated with chemotherapy with 5-fluorouracil. ( Aranda Aguilar, E; de la Haba Rodríguez, JR; Gómez España, MA; Méndez Vidal, MJ; Morales Chamorro, R; Rubio Pérez, MJ; Serrano Blanch, R, 2005) |
| "DPD deficiency was identified phenotypically by both enzyme assay and uracil breath test, and genotypically by denaturing high-performance liquid chromatography." | 1.33 | Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. ( Diasio, RB; Ezzeldin, HH; Lee, AM; Mattison, LK, 2005) |
| " A reduction in irinotecan dosage or use of an alternative agent may be warranted in patients with risk factors for toxicity." | 1.33 | Individualizing chemotherapeutic treatment of colorectal cancer. ( Crews, KR, 2006) |
| "A 37-year-old female with gastric cancer underwent a curative operation, followed by adjuvant chemotherapy consisting of 5-FU and epirubicin." | 1.33 | Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency. ( Baek, JH; Hong, YJ; Kim, DH; Kim, JG; Kim, SN; Lee, KB; Sohn, SK, 2006) |
| "This patient with DPD deficiency manifested a variant of HFS." | 1.33 | Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. ( Diasio, R; Elfiky, A; Saif, MW, 2006) |
| " Comparison of the U/UH2 ratios with a reference, non-toxic population, showed abnormal values suggesting impaired DPD activity in 57 out of the 80 toxic patients (71%) included in this study, and in 4 out of 5 patients (80%) with a fatal outcome." | 1.33 | A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. ( Blanquicett, C; Blesius, A; Boyer, JC; Ciccolini, J; Dahan, L; Duffaud, F; Durand, A; Evrard, A; Favre, R; Lacarelle, B; Mercier, C; Milano, G; Richard, K; Seitz, JF, 2006) |
| "In addition to this study we analyzed a DPD deficiency case and a DHPuria case." | 1.30 | Possible prediction of adverse reactions to fluorouracil by the measurement of urinary dihydrothymine and thymine. ( Dobashi, K; Hayashi, K; Kidouchi, K; Kondou, M; Kouwaki, M; Sumi, S; Togari, H; Wada, Y, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.76) | 18.2507 |
| 2000's | 44 (33.33) | 29.6817 |
| 2010's | 55 (41.67) | 24.3611 |
| 2020's | 32 (24.24) | 2.80 |
| Authors | Studies |
|---|---|
| Jeong, SH | 1 |
| Chavani, O | 1 |
| Burns, K | 2 |
| Porter, D | 2 |
| Findlay, M | 2 |
| Helsby, N | 2 |
| Strother, M | 1 |
| Kang, J | 1 |
| Kim, AH | 1 |
| Jeon, I | 1 |
| Oh, J | 1 |
| Jang, IJ | 1 |
| Lee, S | 1 |
| Cho, JY | 1 |
| Wang, L | 1 |
| Howlett, S | 1 |
| Essapen, S | 1 |
| Nagahisa, S | 1 |
| Watanabe, M | 1 |
| Minagi, H | 1 |
| Ogawa, T | 1 |
| Araki, H | 1 |
| Kimura, Y | 1 |
| Taniguchi, F | 1 |
| Arata, T | 1 |
| Katsuda, K | 1 |
| Tanakaya, K | 1 |
| Aoki, H | 1 |
| Hagiwara, Y | 1 |
| Yamamoto, Y | 1 |
| Inagaki, Y | 1 |
| Tomisaki, R | 1 |
| Tsuji, M | 1 |
| Fukuda, S | 2 |
| Onoda, T | 1 |
| Suzuki, H | 2 |
| Niisato, Y | 1 |
| Tange, Y | 1 |
| Ikeda, N | 1 |
| Yamada, K | 1 |
| Kobayashi, M | 1 |
| Akutsu, D | 1 |
| Yamada, T | 1 |
| Moriwaki, T | 1 |
| Narasaka, T | 1 |
| Tsuchiya, K | 1 |
| Koo, K | 1 |
| Pasternak, AL | 1 |
| Henry, NL | 1 |
| Sahai, V | 1 |
| Hertz, DL | 1 |
| Launay, M | 9 |
| Guitton, J | 6 |
| Balluet, R | 1 |
| Moreau, A | 1 |
| Phelip, JM | 1 |
| Tholance, Y | 1 |
| Gonzalo, P | 1 |
| White, C | 1 |
| Scott, RJ | 1 |
| Paul, C | 1 |
| Ziolkowski, A | 1 |
| Mossman, D | 1 |
| Fox, SB | 1 |
| Michael, M | 1 |
| Ackland, S | 1 |
| Brooks, GA | 1 |
| Tapp, S | 1 |
| Daly, AT | 1 |
| Busam, JA | 1 |
| Tosteson, ANA | 1 |
| Carriat, L | 1 |
| Quaranta, S | 3 |
| Solas, C | 2 |
| Rony, M | 1 |
| Ciccolini, J | 18 |
| Salmani, M | 1 |
| Ghaderi, B | 1 |
| Fotoohi, A | 1 |
| Omid-Shafa'at, R | 1 |
| Vahabzadeh, Z | 1 |
| Fotouhi, O | 1 |
| Abdi, M | 1 |
| Maillard, M | 2 |
| Royer, B | 8 |
| Gautier-Veyret, E | 3 |
| Broutin, S | 1 |
| Tron, C | 3 |
| Le Louedec, F | 1 |
| Richard, D | 1 |
| Alarcan, H | 1 |
| Haufroid, V | 7 |
| Tafzi, N | 1 |
| Schmitt, A | 4 |
| Etienne-Grimaldi, MC | 9 |
| Narjoz, C | 4 |
| Thomas, F | 16 |
| Loriot, MA | 7 |
| Boyer, JC | 9 |
| De Luca, O | 3 |
| Salerno, G | 3 |
| De Bernardini, D | 3 |
| Torre, MS | 3 |
| Simmaco, M | 3 |
| Lionetto, L | 3 |
| Gentile, G | 3 |
| Borro, M | 3 |
| Pallet, N | 2 |
| Boige, V | 1 |
| Chouchana, L | 1 |
| Barin-Le Guellec, C | 1 |
| Zaanan, A | 1 |
| Taieb, J | 1 |
| Lešnjaković, L | 1 |
| Ganoci, L | 1 |
| Bilić, I | 1 |
| Šimičević, L | 1 |
| Mucalo, I | 1 |
| Pleština, S | 1 |
| Božina, N | 1 |
| Sukkarieh, HH | 1 |
| AlSagoor, T | 1 |
| Alnuhait, M | 1 |
| Bustami, R | 1 |
| Bryson, S | 1 |
| Adem, FMK | 1 |
| Abdalla, H | 1 |
| Karbani, G | 1 |
| Arrivé, C | 1 |
| Fonrose, X | 2 |
| Roth, G | 1 |
| Jacquet, E | 1 |
| Brice, A | 2 |
| Chirica, C | 1 |
| Farneti, D | 1 |
| Frenoux, C | 1 |
| Stanke-Labesque, F | 1 |
| Poumeaud, F | 1 |
| Dalenc, F | 1 |
| Mathevet, Q | 1 |
| Eche-Gass, A | 1 |
| De Maio D'Esposito, E | 1 |
| Brac-de-la-Perriere, C | 1 |
| de With, M | 1 |
| Sadlon, A | 1 |
| Cecchin, E | 2 |
| Joerger, M | 1 |
| van Schaik, RHN | 1 |
| Mathijssen, RHJ | 1 |
| Largiadèr, CR | 1 |
| Derain, L | 1 |
| Parant, F | 1 |
| Cunha-Junior, GF | 2 |
| Bastos-Rodrigues, L | 2 |
| Azevedo, PG | 1 |
| Bicalho, MA | 1 |
| Magno, LAV | 1 |
| De Marco, L | 2 |
| Coelho, LG | 2 |
| Correia Pinheiro, L | 1 |
| Durand, J | 1 |
| Dogné, JM | 1 |
| Marin, C | 1 |
| Krache, A | 1 |
| Palmaro, C | 1 |
| Lucas, M | 1 |
| Hilaire, V | 1 |
| Ugdonne, R | 1 |
| De Victor, B | 1 |
| Lacarelle, B | 7 |
| García-González, X | 1 |
| Kaczmarczyk, B | 1 |
| Abarca-Zabalía, J | 1 |
| García-Alfonso, P | 1 |
| Robles, L | 1 |
| Pachón, V | 1 |
| Vaz, Á | 1 |
| Salvador-Martín, S | 1 |
| Sanjurjo-Sáez, M | 1 |
| López-Fernández, LA | 1 |
| Rawlley, B | 1 |
| Diab, O | 1 |
| Al-Rajabi, R | 1 |
| Carroll, E | 1 |
| Melancon, T | 1 |
| Kasi, A | 1 |
| Lemaitre, F | 2 |
| Boisteau, E | 1 |
| Sourd, SL | 1 |
| Lièvre, A | 1 |
| Ishiguro, M | 1 |
| Takenaka, R | 1 |
| Ogura, K | 1 |
| Hiratsuka, A | 1 |
| Takeda, H | 1 |
| Kawai, D | 1 |
| Tsugeno, H | 1 |
| Fujiki, S | 1 |
| Okada, H | 1 |
| Casneuf, V | 1 |
| Borbath, I | 1 |
| Van den Eynde, M | 1 |
| Verheezen, Y | 1 |
| Demey, W | 1 |
| Verstraete, AG | 1 |
| Bm Claes, K | 1 |
| Geboes, KP | 1 |
| Andersen, SE | 1 |
| Paulsen, NH | 1 |
| Pfeiffer, P | 1 |
| Qvortrup, C | 1 |
| Damkier, P | 1 |
| Wigle, TJ | 1 |
| Povitz, BL | 1 |
| Medwid, S | 1 |
| Teft, WA | 1 |
| Legan, RM | 1 |
| Lenehan, J | 1 |
| Nevison, S | 1 |
| Panuganty, V | 1 |
| Keller, D | 1 |
| Mailloux, J | 1 |
| Siebring, V | 1 |
| Sarma, S | 1 |
| Choi, YH | 1 |
| Welch, S | 1 |
| Winquist, E | 1 |
| Schwarz, UI | 1 |
| Kim, RB | 1 |
| Boisdron-Celle, M | 5 |
| Capitain, O | 2 |
| Faroux, R | 3 |
| Borg, C | 2 |
| Metges, JP | 1 |
| Galais, MP | 2 |
| Kaassis, M | 2 |
| Bennouna, J | 2 |
| Bouhier-Leporrier, K | 2 |
| Francois, E | 2 |
| Baumgaertner, I | 2 |
| Guerin-Meyer, V | 2 |
| Cojocarasu, O | 2 |
| Roemer-Becuwe, C | 2 |
| Stampfli, C | 2 |
| Rosenfeld, L | 2 |
| Lecompte, T | 2 |
| Berger, V | 2 |
| Morel, A | 4 |
| Gamelin, E | 4 |
| Meulendijks, D | 4 |
| Henricks, LM | 4 |
| Jacobs, BAW | 1 |
| Aliev, A | 2 |
| Deenen, MJ | 4 |
| de Vries, N | 1 |
| Rosing, H | 1 |
| van Werkhoven, E | 1 |
| de Boer, A | 2 |
| Beijnen, JH | 4 |
| Mandigers, CMPW | 1 |
| Soesan, M | 2 |
| Cats, A | 5 |
| Schellens, JHM | 4 |
| Le Guellec, CB | 1 |
| Chatelut, E | 3 |
| Evrard, A | 5 |
| Paci, A | 2 |
| Philippe Metges, J | 1 |
| Barin-Le-Guellec, C | 2 |
| Milano, G | 6 |
| Picard, N | 1 |
| Becquemont, L | 1 |
| Verstuyft, C | 1 |
| Bobin-Dubigeon, C | 1 |
| Harle, A | 1 |
| Poinsignon, V | 1 |
| Hennart, B | 1 |
| Broly, F | 1 |
| Lafay-Chebassier, C | 1 |
| Wozny, AS | 1 |
| Masskouri, F | 2 |
| Penel, N | 2 |
| Garcia, RAG | 1 |
| Saydoff, JA | 1 |
| Bamat, MK | 1 |
| von Borstel, RW | 1 |
| Del Re, M | 1 |
| Danesi, R | 1 |
| Raymond, E | 1 |
| Goirand, F | 1 |
| Paludetto, MN | 1 |
| Guilhaumou, R | 1 |
| Lunenburg, CATC | 1 |
| Dreussi, E | 1 |
| Peters, FP | 1 |
| Fiocco, M | 1 |
| Toffoli, G | 1 |
| Guchelaar, HJ | 4 |
| Swen, JJ | 4 |
| Gelderblom, H | 3 |
| van Merendonk, LN | 1 |
| Robert, J | 1 |
| Mukherji, D | 1 |
| Massih, SA | 1 |
| Tfayli, A | 1 |
| Kanso, M | 1 |
| Faraj, W | 1 |
| Maharjan, AS | 1 |
| McMillin, GA | 1 |
| Patel, GK | 1 |
| Awan, S | 1 |
| Taylor, WR | 1 |
| Pai, S | 1 |
| Frankel, AE | 1 |
| Nelson, C | 1 |
| Wang, B | 1 |
| Hosein, PJ | 1 |
| Singh, AP | 1 |
| Khushman, M | 1 |
| Carni, P | 1 |
| Le Malicot, K | 1 |
| Seitz, JF | 5 |
| Michel, P | 1 |
| Legoux, JL | 1 |
| Bouché, O | 1 |
| André, T | 1 |
| Delaloge, S | 1 |
| Malka, D | 1 |
| Guigay, J | 1 |
| Thariat, J | 1 |
| Ostapowicz, A | 1 |
| Dołegowska, B | 2 |
| Magnani, E | 1 |
| Farnetti, E | 1 |
| Nicoli, D | 1 |
| Casali, B | 1 |
| Savoldi, L | 1 |
| Focaccetti, C | 1 |
| Boni, C | 1 |
| Albini, A | 1 |
| Banzi, M | 1 |
| van Kuilenburg, AB | 12 |
| Maring, JG | 5 |
| Caudle, KE | 1 |
| Thorn, CF | 1 |
| Klein, TE | 1 |
| McLeod, HL | 3 |
| Diasio, RB | 10 |
| Schwab, M | 2 |
| Bolina, MB | 1 |
| Martins, FL | 1 |
| Pianetti, GA | 1 |
| Cesar, IC | 1 |
| Toshima, T | 1 |
| Kodera, M | 1 |
| Yamashita, Y | 1 |
| Oishi, M | 1 |
| Seshimo, K | 1 |
| Yamamura, M | 1 |
| Kato, H | 1 |
| Ikeda, H | 1 |
| Mizuno, K | 1 |
| Bank, PC | 1 |
| Offer, SM | 1 |
| Butterfield, GL | 1 |
| Jerde, CR | 1 |
| Fossum, CC | 1 |
| Wegner, NJ | 1 |
| Toh, JW | 1 |
| Morris, D | 1 |
| Chen, Z | 1 |
| Chen, C | 1 |
| Papanastasopoulos, P | 1 |
| Stebbing, J | 1 |
| Mokrim, M | 1 |
| Aftimos, PG | 1 |
| Errihani, H | 1 |
| Piccart-Gebhart, M | 1 |
| Jedrzychowska, A | 1 |
| Nagai, K | 1 |
| Okuda, Y | 1 |
| Ohara, Y | 1 |
| Yamamoto, M | 1 |
| Falvella, FS | 1 |
| Cheli, S | 1 |
| Martinetti, A | 1 |
| Mazzali, C | 1 |
| Iacovelli, R | 1 |
| Maggi, C | 1 |
| Gariboldi, M | 1 |
| Pierotti, MA | 1 |
| Di Bartolomeo, M | 1 |
| Sottotetti, E | 1 |
| Mennitto, R | 1 |
| Bossi, I | 1 |
| de Braud, F | 1 |
| Clementi, E | 1 |
| Pietrantonio, F | 1 |
| Dhelens, C | 2 |
| Bonadona, A | 2 |
| Chapuis, C | 1 |
| Potton, L | 1 |
| Marsili, S | 1 |
| Bedouch, P | 1 |
| Schwebel, C | 1 |
| van Staveren, MC | 1 |
| Opdam, F | 1 |
| Hennebelle, I | 1 |
| Delmas, C | 1 |
| Lochon, I | 1 |
| Garnier Tixidre, C | 1 |
| Goncalves, A | 1 |
| Delord, JP | 1 |
| Toulas, C | 1 |
| Dahan, L | 5 |
| Duval, M | 1 |
| Rodallec, A | 1 |
| Duluc, M | 1 |
| Kodali, S | 1 |
| Bathini, V | 1 |
| Rava, P | 1 |
| Tipirneni, E | 1 |
| Saif, MW | 8 |
| Jacobs, BA | 1 |
| Rozeman, L | 1 |
| Meijer, J | 2 |
| de Graaf, H | 1 |
| Schellens, JH | 3 |
| Maurer, D | 1 |
| Dobritzsch, D | 1 |
| Meinsma, R | 2 |
| Los, M | 1 |
| Knegt, LC | 1 |
| Zoetekouw, L | 1 |
| Jansen, RL | 1 |
| Dezentjé, V | 1 |
| van Huis-Tanja, LH | 1 |
| van Kampen, RJ | 1 |
| Hertz, JM | 1 |
| Hennekam, RC | 1 |
| Lunenburg, C | 1 |
| Lazar, A | 2 |
| Jetter, A | 1 |
| Schalhorn, A | 2 |
| Terborg, C | 2 |
| Schmalenberg, H | 1 |
| Behnke, D | 2 |
| Schwabe, W | 2 |
| Jabschinsky, K | 2 |
| Hausler, P | 2 |
| Kim, S | 1 |
| Park, DH | 1 |
| Shim, J | 1 |
| Ben Fredj, R | 1 |
| Gross, E | 2 |
| Ben Ahmed, S | 1 |
| Hassine, H | 1 |
| Saguem, S | 1 |
| Prasad, BB | 1 |
| Tiwari, K | 1 |
| Singh, M | 1 |
| Sharma, PS | 1 |
| Patel, AK | 1 |
| Srivastava, S | 1 |
| Moore, S | 1 |
| Ito, T | 1 |
| Yang, CG | 1 |
| Blesius, A | 2 |
| Bagarry-Liegey, D | 1 |
| Brunet, C | 1 |
| Varoquaux, A | 1 |
| Frances, N | 1 |
| Marouani, H | 1 |
| Giovanni, A | 1 |
| Ferri-Dessens, RM | 1 |
| Chefrour, M | 1 |
| Favre, R | 2 |
| Duffaud, F | 2 |
| Zanaret, M | 1 |
| Mercier, C | 6 |
| Coursier, S | 1 |
| Martelet, S | 1 |
| Guillermet, A | 1 |
| Emptoz, J | 1 |
| Villier, C | 1 |
| Bontemps, H | 1 |
| Disel, U | 1 |
| Gürkut, O | 1 |
| Abali, H | 1 |
| Kaleağasi, H | 1 |
| Mertsoylu, H | 1 |
| Ozyilkan, O | 1 |
| Mounier-Boutoille, H | 1 |
| Cauchin, E | 1 |
| Galmiche, JP | 1 |
| Matysiak-Budnik, T | 1 |
| Obi, EE | 1 |
| McDonald, A | 1 |
| Kemp, E | 1 |
| Serdar, MA | 1 |
| Sertoğlu, E | 1 |
| Uyanık, M | 1 |
| Tapan, S | 1 |
| Akın, O | 1 |
| Cihan, M | 1 |
| Terpstra, WE | 2 |
| Boot, H | 1 |
| Cordier, PY | 1 |
| Nau, A | 1 |
| Oliver, M | 1 |
| Peytel, E | 1 |
| Wettergren, Y | 1 |
| Carlsson, G | 1 |
| Odin, E | 1 |
| Gustavsson, B | 1 |
| Tanck, MW | 1 |
| Proost, JH | 1 |
| Li, J | 1 |
| Lee, JJ | 1 |
| Chu, E | 1 |
| Baehring, JM | 1 |
| Greenfield, NP | 1 |
| Maibach, H | 1 |
| Mandigers, CM | 1 |
| Schneider, HB | 1 |
| Becker, H | 1 |
| Fischer, J | 1 |
| Eichelbaum, M | 1 |
| Zanger, UM | 1 |
| Ezzeldin, H | 5 |
| Johnson, MR | 2 |
| Okamoto, Y | 1 |
| Diasio, R | 5 |
| Stroomer, AE | 1 |
| Van Lenthe, H | 1 |
| Abeling, NG | 1 |
| Van Gennip, AH | 3 |
| Hooiveld, EA | 1 |
| Haanen, JB | 1 |
| Westermann, AM | 1 |
| Mattison, LK | 3 |
| Carpenter, M | 1 |
| Modak, A | 2 |
| Mau-Holzmann, UA | 1 |
| Kolb, H | 1 |
| Reichenmiller, HE | 1 |
| Riess, O | 1 |
| Schömig, E | 1 |
| Lim, WT | 1 |
| Schouten, L | 1 |
| Greijdanus, B | 1 |
| de Vries, EG | 1 |
| Uges, DR | 1 |
| Díaz, R | 1 |
| Segura, A | 1 |
| Aparicio, J | 1 |
| Calderero, V | 1 |
| Guerrero, A | 1 |
| Pellín, L | 1 |
| Altundag, O | 1 |
| Altundag, K | 1 |
| Silay, K | 1 |
| Turen, S | 1 |
| Grem, JL | 1 |
| Branca, MA | 1 |
| Morales Chamorro, R | 1 |
| Serrano Blanch, R | 1 |
| Méndez Vidal, MJ | 1 |
| Gómez España, MA | 1 |
| Rubio Pérez, MJ | 1 |
| de la Haba Rodríguez, JR | 1 |
| Aranda Aguilar, E | 1 |
| Al-Sanna'a, NA | 1 |
| Atrak, TM | 1 |
| Abdul-Jabbar, MA | 1 |
| Lee, A | 1 |
| Fourie, J | 2 |
| Richard, K | 2 |
| Dales, JP | 1 |
| Durand, A | 2 |
| Ezzeldin, HH | 1 |
| Lee, AM | 1 |
| Crews, KR | 1 |
| Baek, JH | 1 |
| Kim, JG | 1 |
| Kim, SN | 1 |
| Kim, DH | 1 |
| Sohn, SK | 1 |
| Hong, YJ | 1 |
| Lee, KB | 1 |
| Desmond, RA | 1 |
| Hashmi, S | 1 |
| Mattison, L | 1 |
| Donovan, WB | 1 |
| Elfiky, A | 1 |
| Blanquicett, C | 1 |
| Remaud, G | 1 |
| Traore, S | 1 |
| Poirier, AL | 1 |
| Gamelin, L | 1 |
| Vance, K | 1 |
| Sellers, S | 1 |
| Yen, JL | 1 |
| Kralovánszky, J | 1 |
| Adleff, V | 1 |
| Hitre, E | 1 |
| Pap, E | 1 |
| Réti, A | 1 |
| Komlósi, V | 1 |
| Budai, B | 1 |
| Wilson, KS | 1 |
| Fitzgerald, CA | 1 |
| Barnett, JB | 1 |
| Gill, S | 1 |
| Khoo, KE | 1 |
| Blasco, H | 1 |
| Bougnoux, P | 1 |
| Calais, G | 1 |
| Tournamille, JF | 1 |
| Autret-Leca, E | 1 |
| Le Guellec, C | 1 |
| Seller, S | 1 |
| Sumi, S | 1 |
| Kidouchi, K | 1 |
| Kondou, M | 1 |
| Hayashi, K | 1 |
| Dobashi, K | 1 |
| Kouwaki, M | 1 |
| Togari, H | 1 |
| Wada, Y | 1 |
24 reviews available for fluorouracil and Dihydropyrimidine Dehydrogenase Deficiency
| Article | Year |
|---|---|
Severe Gastrointestinal Disorder Due to Capecitabine Associated with Dihydropyrimidine Dehydrogenase Deficiency: A Case Report and Literature Review.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Fluoroura | 2022 |
Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping.
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2022 |
Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrour | 2023 |
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrour | 2023 |
[Phenotype- or genotype test for dihydropyrimidin dehydrogenase deficiency before treatment with a fluoropyrimidine].
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2021 |
[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrour | 2018 |
[5-fluorouracil therapeutic drug monitoring: Update and recommendations of the STP-PT group of the SFPT and the GPCO-Unicancer].
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2018 |
[Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
Topics: Antineoplastic Agents; Biomarkers; Breath Tests; Capecitabine; Comorbidity; Deoxycytidine; Dihydropy | 2012 |
Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients.
Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as T | 2013 |
[A case in which dihydropyrimidine dehydrogenase deficiency was strongly suspected during adjuvant chemotherapy with capecitabine for colon cancer].
Topics: Aged; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Dihydropyrimidine Dehy | 2013 |
Molecular basis of 5-fluorouracil-related toxicity: lessons from clinical practice.
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2014 |
Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 2014 |
[Pharmacogenetics in oncology: 5-fluorouracil and the dihydropyrimidine dehydrogenase].
Topics: Amino Acid Substitution; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency | 2008 |
Unanticipated toxicity to capecitabine.
Topics: Antimetabolites, Antineoplastic; Black or African American; Breast Neoplasms; Capecitabine; Deoxycyt | 2009 |
Children's toxicology from bench to bed--Liver injury (1): Drug-induced metabolic disturbance--toxicity of 5-FU for pyrimidine metabolic disorders and pivalic acid for carnitine metabolism.
Topics: Amidohydrolases; Animals; Anti-Bacterial Agents; Antineoplastic Agents; Carnitine; Cephalosporins; C | 2009 |
Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?
Topics: Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Colorectal Neoplasms; Dihydropyrimidin | 2010 |
Impact of dihydropyrimidine dehydrogenase on 5-fluorouracil treatment in cancer patients.
Topics: Antimetabolites, Antineoplastic; Dermatitis; Diarrhea; Dihydropyrimidine Dehydrogenase Deficiency; D | 2003 |
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydropyrimidine Dehydrogenase Deficiency; D | 2004 |
Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration.
Topics: Antimetabolites, Antineoplastic; Diagnosis, Differential; Dihydropyrimidine Dehydrogenase Deficiency | 2004 |
Pyrimidine degradation defects and severe 5-fluorouracil toxicity.
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2004 |
Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
Topics: Antidotes; Antimetabolites, Antineoplastic; Biotransformation; Deoxyuracil Nucleotides; Diarrhea; Di | 2004 |
Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question.
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Fluorouracil; Humans; M | 2006 |
Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehyd | 2006 |
Should DPD analysis be required prior to prescribing fluoropyrimidines?
Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Dihydropyrimidine Dehydrogena | 2007 |
2 trials available for fluorouracil and Dihydropyrimidine Dehydrogenase Deficiency
| Article | Year |
|---|---|
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cohort Studies; Dihydropyrimidine D | 2017 |
DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Def | 2011 |
106 other studies available for fluorouracil and Dihydropyrimidine Dehydrogenase Deficiency
| Article | Year |
|---|---|
Severe 5-Fluorouracil-Associated Gastrointestinal Toxicity Unexplained by Dihydropyrimidine Dehydrogenase Deficiency and Renal Impairment: Should We Be Investigating Other Elimination Pathways to Assess the Risk of 5-Fluorouracil Toxicity?
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Drug-Related Side Effec | 2021 |
Testing for dihydropyrimidine dehydrogenase deficiency in New Zealand to improve the safe use of 5-fluorouracil and capecitabine in cancer patients.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Dihydropyrimidine Dehydrogenase Def | 2021 |
Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase.
Topics: Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans | 2022 |
Treating patients with dihydropyrimidine dehydrogenase (DPD) deficiency with fluoropyrimidine chemotherapy since the onset of routine prospective testing-The experience of a large oncology center in the United Kingdom.
Topics: Antimetabolites, Antineoplastic; Cancer Care Facilities; Capecitabine; Dihydropyrimidine Dehydrogena | 2022 |
[A Case of Colon Cancer with Suspected DPD Deficiency Causing Severe Adverse Effects following Adjuvant Chemotherapy with Capecitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectom | 2021 |
Survey of US Medical Oncologists' Practices and Beliefs Regarding
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Dihydropyrimidine Dehydrogenase Def | 2022 |
Clinical considerations for DPD deficiency testing in advanced cancer patients: tumor lysis syndrome should be considered as a major interference.
Topics: Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans | 2022 |
Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer.
Topics: Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Cost-Benefit Analysis; Dihydropyrimidine De | 2022 |
Renal impairment and DPD testing: Watch out for false-positive results!
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrour | 2022 |
Introducing a simple and cost-effective RT-PCR protocol for detection of DPYD*2A polymorphism: the first study in Kurdish population.
Topics: Antimetabolites, Antineoplastic; Cost-Benefit Analysis; Dihydropyrimidine Dehydrogenase Deficiency; | 2022 |
Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency.
Topics: Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans | 2023 |
Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!
Topics: Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans | 2023 |
Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!
Topics: Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans | 2023 |
Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!
Topics: Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans | 2023 |
Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!
Topics: Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans | 2023 |
Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!
Topics: Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans | 2023 |
Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!
Topics: Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans | 2023 |
Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!
Topics: Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans | 2023 |
Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!
Topics: Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans | 2023 |
Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!
Topics: Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans | 2023 |
Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2022 |
Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2022 |
Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2022 |
Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2022 |
Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2022 |
Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2022 |
Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2022 |
Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2022 |
Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2022 |
Awareness and attitudes of oncology specialists toward dihydropyrimidine dehydrogenase testing in Saudi Arabia.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cross-Sectional Studies; Dihydropyrimidine Dehydrogen | 2023 |
Discrepancies between dihydropyrimidine dehydrogenase phenotyping and genotyping: What are the explanatory factors?
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrour | 2023 |
Phenotype/Genotype Discrepancy of DPD Deficiency Screening in a Patient With Severe Capecitabine Toxicity: A Case Report.
Topics: Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Fluorouracil; Genotype; Humans; Phenotype | 2023 |
Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe.
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2023 |
Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping.
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2023 |
Prevalence of the DPYD variant (Y186C) in Brazilian individuals of African ancestry.
Topics: Antimetabolites, Antineoplastic; Black People; Brazil; Capecitabine; Dihydropyrimidine Dehydrogenase | 2019 |
An Application of Machine Learning in Pharmacovigilance: Estimating Likely Patient Genotype From Phenotypical Manifestations of Fluoropyrimidine Toxicity.
Topics: Antimetabolites, Antineoplastic; Databases, Factual; Dihydropyrimidine Dehydrogenase Deficiency; Flu | 2020 |
A Simple and Rapid UPLC-UV Method for Detecting DPD Deficiency in Patients With Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; Chromatog | 2020 |
New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Computer Simulation; | 2020 |
Dual deficiency of DPD and UGT1A1 in a case of colon cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2020 |
When helping the minority of patients may hurt the majority: The case for DPD phenotyping and 5-fluorouracil therapeutic drug monitoring.
Topics: Aged; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Deh | 2021 |
A Japanese Patient with Gastric Cancer and Dihydropyrimidine Dehydrogenase Deficiency Presenting with DPYD Variants.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Contraindications, Drug; Dihydropyrimidine Dehydrog | 2020 |
Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur).
Topics: Antimetabolites, Antineoplastic; Belgium; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; | 2022 |
Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events.
Topics: Aged; Antimetabolites, Antineoplastic; Canada; Capecitabine; Dihydropyrimidine Dehydrogenase Deficie | 2021 |
Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation.
Topics: Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluoro | 2021 |
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; | 2017 |
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing.
Topics: Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Ef | 2017 |
In reply.
Topics: Dihydropyrimidine Dehydrogenase Deficiency; Fluorouracil; Humans | 2017 |
[Requirement of DPD deficiency screening before prescription of fluoropyrimidines].
Topics: Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluoro | 2018 |
Prompt treatment with uridine triacetate improves survival and reduces toxicity due to fluorouracil and capecitabine overdose or dihydropyrimidine dehydrogenase deficiency.
Topics: Acetates; Animals; Antidotes; Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehyd | 2018 |
Predicting fluoropyrimidine-related toxicity: turning wish to will, the PAMM-EORTC position.
Topics: Consensus; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Dose-Resp | 2018 |
Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Capecitabine; Chemoradioth | 2018 |
Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2019 |
[5-FU: At last!]
Topics: Acetates; Antidotes; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Fl | 2019 |
Three different polymorphisms of the DPYD gene associated with severe toxicity following administration of 5-FU: a case report.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dih | 2019 |
Fluoropyrimidines and DPD testing: is there truly an inexorable link?
Topics: Antineoplastic Agents; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP | 2019 |
The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2019 |
[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biology; Biomedical | 2019 |
Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Colonic Neoplasms | 2013 |
Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Defici | 2013 |
(13)C-uracil breath test to predict 5-fluorouracil toxicity in gastrointestinal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breath Tests; Carbon Isotopes; Dihy | 2013 |
Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase (DPD) splice site variant: the need for further revision of dose and schedule.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Deoxycytidine; Dihydropyr | 2014 |
microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites.
Topics: Animals; Binding Sites; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NAD | 2014 |
Near fatal 5-FU gut toxicity post surgery--remarkable effect of high-dose sucralfate.
Topics: Adult; Anti-Ulcer Agents; Antimetabolites, Antineoplastic; Combined Modality Therapy; Dihydropyrimid | 2015 |
[Dihydropirymidine dehydrogenase (DPD)--a toxicity marker for 5-fluorouracil?].
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Dihydropyrimidine Dehydrogenase Deficiency; Dihy | 2013 |
[Suspected dihydropyrimidine dehydrogenase deficiency in a patient receiving capecitabine as adjuvant chemotherapy after colon resection].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Deoxycytidin | 2015 |
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dih | 2015 |
Lethal 5-fluorouracil toxicity in a colorectal patient with severe dihydropyrimidine dehydrogenase (DPD) deficiency.
Topics: Colorectal Neoplasms; Dihydropyrimidine Dehydrogenase Deficiency; Fatal Outcome; Female; Fluorouraci | 2016 |
Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2015 |
Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.
Topics: Adult; Antimetabolites, Antineoplastic; Biotransformation; Dihydropyrimidine Dehydrogenase Deficienc | 2016 |
Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Digestive System Neoplasms; Dihydro | 2016 |
Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dose-Resp | 2017 |
Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.
Topics: Acetates; Aged; Antidotes; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficien | 2016 |
Current insights into the impact of dihydropyrimidine dehydrogenase deficiency in patients receiving treatment with 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2016 |
Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dih | 2016 |
Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dih | 2017 |
Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil.
Topics: Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dose-Response Relationship, Drug; Fluorour | 2017 |
Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14+1G > A mutation in the dihydropyrimidine dehydrogenase gene.
Topics: Antineoplastic Agents; Area Under Curve; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil D | 2008 |
Thymidylate synthase and dihydropyrimidine dehydrogenase levels are associated with response to 5-fluorouracil in Caenorhabditis elegans.
Topics: Amino Acid Sequence; Animals; Caenorhabditis elegans; Dihydropyrimidine Dehydrogenase Deficiency; Di | 2008 |
The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers; Chromatography, High Pressure Liquid; Colo | 2009 |
Ultratrace analysis of uracil and 5-fluorouracil by molecularly imprinted polymer brushes grafted to silylated solid-phase microextraction fiber in combination with complementary molecularly imprinted polymer-based sensor.
Topics: Benzenesulfonates; Binding Sites; Dihydropyrimidine Dehydrogenase Deficiency; Fluorouracil; Humans; | 2009 |
[Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycyti | 2010 |
Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Atrophy; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehyd | 2010 |
Lethal outcome of 5-fluorouracil infusion in a patient with a total DPD deficiency and a double DPYD and UTG1A1 gene mutation.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Dihydropyrimidine Dehydrog | 2010 |
A bilateral cicatricial ectropion and bilateral upper lid shortening caused by 5-fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Dihydropyrimidine Dehydrogenase Defic | 2011 |
Determination of 5-fluorouracil and dihydrofluorouracil levels by using a liquid chromatography-tandem mass spectrometry method for evaluation of dihydropyrimidine dehydrogenase enzyme activity.
Topics: Antimetabolites, Antineoplastic; Biotransformation; Chromatography, High Pressure Liquid; Dihydropyr | 2011 |
Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Defici | 2010 |
5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases.
Topics: Aged; Antimetabolites, Antineoplastic; Brain; Dihydropyrimidine Dehydrogenase Deficiency; Electroenc | 2011 |
Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2012 |
Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bayes Theorem; Biotransformation; Dihydropyrimidine De | 2012 |
Reversible leukoencephalopathy with stroke-like presentation in a patient with 5-dihydropyrimidine dehydrogenase deficiency treated with continuous 5-fluorouracil infusion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dihydropy | 2012 |
Pharmacogenomic biomarkers in dermatologic drugs.
Topics: Androstenes; Aryl Hydrocarbon Hydroxylases; Biomarkers; Chloroquine; Cytochrome P-450 CYP2C19; Cytoc | 2013 |
[Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency].
Topics: Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency | 2012 |
Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography.
Topics: Alleles; Antimetabolites, Antineoplastic; Base Sequence; Chromatography, High Pressure Liquid; Dihyd | 2003 |
Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity.
Topics: Aged; Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Dihydropyrimidine Dehyd | 2003 |
New insights in dihydropyrimidine dehydrogenase deficiency: a pivotal role for beta-aminoisobutyric acid?
Topics: Aminoisobutyric Acids; beta-Alanine; Brain Diseases, Metabolic, Inborn; Dihydropyrimidine Dehydrogen | 2004 |
[Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Defici | 2004 |
Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test.
Topics: Antimetabolites, Antineoplastic; Breath Tests; Carbon Dioxide; Carbon Isotopes; Chromatography, High | 2004 |
Multiple organ failure due to 5-fluorouracil chemotherapy in a patient with a rare dihydropyrimidine dehydrogenase gene variant.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Cecal Neoplasms; Dihydropyrimidine Dehydrogenase Defic | 2004 |
Should screening for DPD deficiency be mandatory before 5-FU exposure?
Topics: Antineoplastic Agents; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP | 2004 |
A simple and sensitive fully validated HPLC-UV method for the determination of 5-fluorouracil and its metabolite 5,6-dihydrofluorouracil in plasma.
Topics: Chromatography, High Pressure Liquid; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehy | 2005 |
Lethal toxicity after 5-fluorouracil chemotherapy and its possible relationship to dihydropyrimidine dehydrogenase deficiency: a case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Deficiency Diseases; Dihydropyrimidine Dehydr | 2004 |
Gender differences in the dihydropyrimidine dehydrogenase expression may contribute to higher toxicity in women treated with 5-fluorouracil therapy.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydro | 2005 |
Screening for dihydropyrimidine dehydrogenase deficiency.
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Fluorouracil; Humans; L | 2005 |
BiDil raises questions about race as a marker.
Topics: Biomarkers; Black People; Clinical Trials as Topic; Dihydropyrimidine Dehydrogenase Deficiency; Dihy | 2005 |
Pseudomembranous colitis associated with chemotherapy with 5-fluorouracil.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Clostridioides difficile; Dihydropyrimidine Dehydro | 2005 |
Dihydropyrimidine dehydrogenase deficiency presenting at birth.
Topics: Age of Onset; Antimetabolites; Binding Sites; Digestive System Abnormalities; Dihydropyrimidine Dehy | 2005 |
Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Capecitabine; Carcinoma, Hepatocellul | 2006 |
Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.
Topics: Adult; Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; CpG Islands; Dihydropy | 2005 |
Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Contraindications; Deoxycy | 2006 |
Individualizing chemotherapeutic treatment of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bilirubin; Biomark | 2006 |
Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Dihydropyrimidine De | 2006 |
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians.
Topics: Adult; Aged; Anemia; Black or African American; Breath Tests; Carbon Dioxide; Colorectal Neoplasms; | 2006 |
Peripheral neuropathy exacerbation associated with topical 5-fluorouracil.
Topics: Aged; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Deh | 2006 |
Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deficiency Diseases; Deoxycyt | 2006 |
A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Dihydropyrimidin | 2006 |
5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Def | 2007 |
DPYD*2A mutation: the most common mutation associated with DPD deficiency.
Topics: Adenocarcinoma; Aged; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP) | 2007 |
[Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2007 |
Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydropyrimi | 2007 |
A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Dihydropyrimi | 2008 |
Atypical toxicity associated with 5-Fluororacil in a DPD-deficient patient with pancreatic cancer. Is ethnicity a risk factor?
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; D | 2008 |
Possible prediction of adverse reactions to fluorouracil by the measurement of urinary dihydrothymine and thymine.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Child; Child, Preschool; Dihydropyrimidine Dehyd | 1998 |